This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Journalology/ Peer Review/ Authorship  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 80 words of the full text and any section headings.

In reply

We completely agree with Bjarnason. The APC trial indicates that no selective cyclooxygenase-2 (COX-2) inhibitor is risk free, but the bulk of the available evidence suggests that celecoxib in routinely used doses (eg, up to 200 mg/d) has a lower risk of cardiovascular toxic effects compared with rofecoxib or valdecoxib.

AUTHOR INFORMATION
Correspondence: Dr Solomon, Harvard Medical School, Division of Pharmacoepidemiology, Brigham and Women’s Hospital, 1620 Tremont St, Suite 3030, Boston, MA 02120 (dhsolomon@partners.org).

Daniel H. Solomon, MD, MPH; Jerry Avorn, MD

Arch Intern Med. 2005;165:1440.

RELATED ARTICLES

Inconsistency in the Editorial Process in Archives of Internal Medicine?
Nina H. Bjarnason
Arch Intern Med. 2005;165(12):1439-1440.
EXTRACT | FULL TEXT  

Inconsistency in the Editorial Process in Archives of Internal Medicine?—Reply
Philip Greenland
Arch Intern Med. 2005;165(12):1440.
EXTRACT | FULL TEXT  

Coxibs, Science, and the Public Trust
Daniel H. Solomon and Jerry Avorn
Arch Intern Med. 2005;165(2):158-160.
EXTRACT | FULL TEXT